Search results
Results from the WOW.Com Content Network
Montelukast, sold under the brand name Singulair among others, is a medication used in the maintenance treatment of asthma. [6] It is generally less preferred for this use than inhaled corticosteroids. [6] It is not useful for acute asthma attacks. [6] Other uses include allergic rhinitis and hives of long duration. [6]
Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls. Terfenadine (Seldane, Triludan) 1997–1998 France, South Africa, Oman, others, US Prolonged QT interval; ventricular tachycardia [2] [3]
The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone, according to FDA slides reviewed by Reuters. The FDA has ...
Singulair, originally sold by Merck & Co., is a prescription drug that was launched in 1998 and is used to prevent and treat symptoms of asthma and allergies, according to the Cleveland Clinic, by ...
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
Levocetirizine was approved for medical use in the United States in 2007, [3] and is available as a generic medication. [4] In 2022, it was the 152nd most commonly prescribed medication in the United States, with more than 3 million prescriptions. [7] [8]
This is the latest setback for the experimental drug, vibostolimab, and the related promising new class of immunotherapies called anti-TIGIT. Merck was testing vibostolimab along with Keytruda ...
Specific medications for asthma are broadly classified into fast-acting and long-acting categories. [156] [157] The medications listed below have demonstrated efficacy in improving asthma symptoms; however, real world use-effectiveness is limited as around half of people with asthma worldwide remain sub-optimally controlled, even when treated.